Your browser doesn't support javascript.
loading
D-galactose Supplementation for the Treatment of Mild Malformation of Cortical Development with Oligodendroglial Hyperplasia in Epilepsy (MOGHE): A Pilot Trial of Precision Medicine After Epilepsy Surgery.
Aledo-Serrano, Ángel; Valls-Carbó, Adrián; Fenger, Christina D; Groeppel, Gudrun; Hartlieb, Till; Pascual, Irene; Herraez, Erika; Cabal, Borja; García-Morales, Irene; Toledano, Rafael; Budke, Marcelo; Beltran-Corbellini, Álvaro; Baldassari, Sara; Coras, Roland; Kobow, Katja; Herrera, David M; Del Barrio, Antonio; Dahl, Hans Atli; Del Pino, Isabel; Baulac, Stéphanie; Blumcke, Ingmar; Møller, Rikke S; Gil-Nagel, Antonio.
Afiliação
  • Aledo-Serrano Á; Epilepsy and Neurogenetics Program, Ruber Internacional Hospital, La Masó 34, 28034, Madrid, Spain. aaledo@synaptia.org.
  • Valls-Carbó A; Initiative for Neuroscience (INCE) Foundation, Madrid, Spain. aaledo@synaptia.org.
  • Fenger CD; Neuroscience Institute, Vithas Madrid La Milagrosa University Hospital, Vithas Hospital Group, Madrid, Spain. aaledo@synaptia.org.
  • Groeppel G; Epilepsy and Neurogenetics Program, Ruber Internacional Hospital, La Masó 34, 28034, Madrid, Spain.
  • Hartlieb T; Initiative for Neuroscience (INCE) Foundation, Madrid, Spain.
  • Pascual I; Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre, Dianalund, Denmark.
  • Herraez E; Amplexa Genetics A/S (H.A.D.), Odense, Denmark.
  • Cabal B; Department of Paediatrics and Adolescent Medicine and Department of Neurology, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria.
  • García-Morales I; Center for Pediatric Neurology, Neurorehabilitation, and Epileptology, Schoen Clinic, Vogtareuth, Germany.
  • Toledano R; Research Institute "Rehabilitation, " PMU Salzburg, Transition, PalliationSalzburg, Austria.
  • Budke M; Epilepsy and Neurogenetics Program, Ruber Internacional Hospital, La Masó 34, 28034, Madrid, Spain.
  • Beltran-Corbellini Á; Epilepsy and Neurogenetics Program, Ruber Internacional Hospital, La Masó 34, 28034, Madrid, Spain.
  • Baldassari S; Department of Neurophysiology, Rey Juan Carlos University Hospital, Madrid, Spain.
  • Coras R; Epilepsy and Neurogenetics Program, Ruber Internacional Hospital, La Masó 34, 28034, Madrid, Spain.
  • Kobow K; Department of Neurology, Puerta de Hierro University Hospital, Madrid, Spain.
  • Herrera DM; Epilepsy and Neurogenetics Program, Ruber Internacional Hospital, La Masó 34, 28034, Madrid, Spain.
  • Del Barrio A; Epilepsy Unit, Department of Neurology, Clinico San Carlos University Hospital, Madrid, Spain.
  • Dahl HA; Epilepsy and Neurogenetics Program, Ruber Internacional Hospital, La Masó 34, 28034, Madrid, Spain.
  • Del Pino I; Epilepsy Unit, Department of Neurology, Clinico San Carlos University Hospital, Madrid, Spain.
  • Baulac S; Epilepsy and Neurogenetics Program, Ruber Internacional Hospital, La Masó 34, 28034, Madrid, Spain.
  • Blumcke I; Department of Neurosurgery, Niño Jesus University Hospital, Madrid, Spain.
  • Møller RS; Epilepsy and Neurogenetics Program, Ruber Internacional Hospital, La Masó 34, 28034, Madrid, Spain.
  • Gil-Nagel A; Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Paris, France.
Neurotherapeutics ; 20(5): 1294-1304, 2023 09.
Article em En | MEDLINE | ID: mdl-37278968
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Epilepsia / Galactose Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Neurotherapeutics Assunto da revista: NEUROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Epilepsia / Galactose Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Neurotherapeutics Assunto da revista: NEUROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha